Home › Waldenstrom Macroglobulinemia › New Jersey
Waldenstrom Macroglobulinemia clinical trials in New Jersey
7 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in New Jersey.
Cities in New Jersey
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memoral Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07231952Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Astera Cancer Care ( Site 2732), East Brunswick
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT04728893A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.